Ende Pan, Ph.D. joined atai Life Science in 2022. Dr. Pan has over 8 years of experience in the pharma and biotech industry. He held several research and development positions, including most recently at Frequency Therapeutics where he was senior scientist and responsible for analytical development of drug substance and drug product of clinical-stage products, at Amgen where he focused on the drug substances of clinical product Lumakras™ and commercial product Otezla®, and at Warp Drive Bio, where he contributed to the analytical activities of multiple types of natural product derived compounds from genetically engineered bacteria.

Dr. Pan holds BS and MS degrees in Chemistry from Xiamen University, China, He received his Ph.D. in Chemistry from Virginia Tech and he conducted postdoctoral training in UT Southwestern Medical Center at Dallas.